Microneedles Breakthrough Brings 3M One Step Closer to Introducing New Alternative Drug Delivery Method
Getting an injection at the doctor’s office typically does not rank high on many people’s wish list. Thanks to 3M scientists’ know-how, the day is getting closer when patients may be receiving their prescription medications at home via microscopic needles. Pharmaceutical and biotechnology companies can now partner with 3M on development and conducting clinical trials using its 3M Hollow Microstructured Transdermal System (hMTS). Patient-friendly and easy to use, 3M hMTS is designed to open new opportunities for pharmaceutical companies and patients.
The device’s availability for clinical trials comes after conducting a number of studies and design verification tests. Based on 3M microreplication technology, pharmaceutical and biotech companies can take advantage of this patient-friendly hollow microneedle device for difficult-to-deliver biologics.
To reach this current stage of clinical readiness with the hMTS device, 3M has undertaken a rigorous process, including finalizing the device design, manufacturing critical components from medical grade materials, establishing GMP array manufacturing and device assembly, as well as filing documentation with FDA.
3M conducted a human tolerability study with the goal of selecting the appropriate microneedle array for use in clinical studies. The outcome of this study found very good delivery times for 2 mL (less than 2 minutes on average). These results provide foundational data in assessing the safety of the device. Clinical supplies are now available for assessment in potential development partners' trials.
“From the foundation laid by our recent human study, we are excited to extend our hollow microneedle device and expertise to companies who are ready for clinical studies. Pharma companies can now evaluate 3M hMTS in their clinical trials as a delivery system for a new drug product or a product line extension,” said Ingrid Blair, Vice President, Business and Marketing, 3M Drug Delivery Systems. “Keeping patient preference top of mind is key and with this new system, pharmaceutical companies have more options to satisfy patients.”
“3M hMTS continues to demonstrate a number of unique benefits, including reproducible intradermal delivery, a proven ability to deliver formulations up to 2 mL with various viscosities, and API-dependent PK profile benefits,” continued Blair. “Its patient-friendly features and the ability for patients to easily self-administer open new opportunities to move treatments out of the clinic and into the patient’s own home. We are looking forward to working with pharmaceutical partners to provide this microneedle drug delivery alternative.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance